We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+9.82%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$6.17B
AUM Growth
+$18.3M
Cap. Flow
-$273M
Cap. Flow %
-4.42%
Top 10 Hldgs %
39.22%
Holding
178
New
12
Increased
57
Reduced
71
Closed
15

Top Buys

Rank Stock Value
1
EVH icon
Evolent Health
EVH
+$25.8M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$23.3M
3
EXAS
Exact Sciences
EXAS
+$16.4M
4
ABT icon
Abbott
ABT
+$15.1M
5
TNDM icon
Tandem Diabetes Care
TNDM
+$13M

Top Sells

Rank Stock Value
1
INSM icon
Insmed
INSM
+$36.6M
2
BIO icon
Bio-Rad Laboratories Class A
BIO
+$34.7M
3
CRL icon
Charles River Laboratories
CRL
+$33.2M
4
ARGX icon
argenx
ARGX
+$29.8M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$28.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.92%
2 Industrials 0.04%
3 Communication Services 0.02%
4 Technology 0.01%
5 Consumer Discretionary 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DXCM icon
26
DexCom
DXCM
$29.3B
$68.2M 1.1%
1,017,038
-251,649
-20% -$20.7M
ARVN icon
27
Arvinas
ARVN
$527M
$58.8M 0.95%
2,386,600
-4,200
-0.2% -$110K
PEN icon
28
Penumbra
PEN
$12.5B
$53M 0.86%
272,683
-9,366
-3% -$1.77M
RLAY icon
29
Relay Therapeutics
RLAY
$4.41B
$52.2M 0.85%
7,377,184
+1,000,069
+16% +$7.47M
OPCH icon
30
Option Care Health
OPCH
$3.42B
$51.8M 0.84%
1,654,878
+237,999
+17% +$7.3M
GEHC icon
31
GE HealthCare
GEHC
$28.6B
$49.9M 0.81%
531,967
+10,950
+2% +$919K
PRCT icon
32
Procept Biorobotics
PRCT
$1.09B
$49.1M 0.8%
612,691
-56,358
-8% -$4M
EPIX
33
DELISTED
ESSA Pharma
EPIX
$47.8M 0.77%
7,879,583
-10,000
-0.1% -$54.9K
ZBH icon
34
Zimmer Biomet
ZBH
$17.6B
$46.7M 0.76%
432,805
-16,276
-4% -$1.78M
HCA icon
35
HCA Healthcare
HCA
$82.3B
$46.5M 0.75%
114,525
-7,779
-6% -$2.85M
ELV icon
36
Elevance Health
ELV
$82.2B
$46.5M 0.75%
89,328
-12,221
-12% -$6.53M
IDXX icon
37
Idexx Laboratories
IDXX
$44.8B
$46.1M 0.75%
91,279
-2,079
-2% -$1.01M
COO icon
38
Cooper Companies
COO
$13.9B
$43.8M 0.71%
397,373
– –
SRPT icon
39
Sarepta Therapeutics
SRPT
$1.85B
$43M 0.7%
344,348
+92,027
+36% +$12.7M
EXEL icon
40
Exelixis
EXEL
$14.2B
$41.5M 0.67%
1,600,000
-203,200
-11% -$5.05M
INSP icon
41
Inspire Medical Systems
INSP
$1.47B
$41.2M 0.67%
195,080
+70,356
+56% +$12.2M
CI icon
42
Cigna
CI
$74.8B
$41M 0.66%
118,407
-4,683
-4% -$1.61M
LLY icon
43
Eli Lilly
LLY
$1.05T
$39.2M 0.64%
44,246
-5,428
-11% -$4.88M
RMD icon
44
ResMed
RMD
$28.3B
$39.1M 0.63%
160,128
+4,247
+3% +$949K
INSM icon
45
Insmed
INSM
$23.6B
$38.4M 0.62%
525,434
-496,266
-49% -$36.6M
EWTX icon
46
Edgewise Therapeutics
EWTX
$4.38B
$38.1M 0.62%
1,428,929
– –
IMCR icon
47
Immunocore
IMCR
$1.77B
$37.5M 0.61%
1,205,464
+50,810
+4% +$1.85M
BEAM icon
48
Beam Therapeutics
BEAM
$2.89B
$37.2M 0.6%
1,518,121
+100,000
+7% +$2.58M
BDTX icon
49
Black Diamond Therapeutics
BDTX
$104M
$37.1M 0.6%
8,517,839
– –
ALGN icon
50
Align Technology
ALGN
$12.6B
$36.6M 0.59%
143,996
+14
+0% +$3.3K
1
2
3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q3 2024 Portfolio in Review

As of Q3 2024, Bellevue Group held 178 positions worth $6.17B, up 0.3% from $6.15B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Bellevue Group withdrew a net $273M in Q3 2024, closing 15 positions and reducing 71 holdings. Its most notable exit was Silk Road Medical, Inc. Common Stock, an estimated $23.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Industrials and Communication Services.

Against the trend, Bellevue Group opened a new position in Terns Pharmaceuticals worth $8.69M.

  • Bellevue Group's largest Q3 2024 buy was Terns Pharmaceuticals: 1,042,135 shares worth $8.69M.
  • Bellevue Group added most to Evolent Health in Q3 2024, an estimated $25.8M increase.
  • Bellevue Group's biggest Q3 2024 reduction was Insmed, cutting an estimated $36.6M.
  • Bellevue Group fully exited Silk Road Medical, Inc. Common Stock in Q3 2024, selling an estimated $23.1M.
  • Bellevue Group's ten largest holdings make up 39% of its $6.17B portfolio in Q3 2024.
  • Bellevue Group opened 12 new positions and closed 15 in Q3 2024.
  • Bellevue Group's portfolio value rose 0.3% quarter-over-quarter to $6.17B.

Based on Bellevue Group's 13F filing for Q3 2024, filed 14 Nov 2024.